MCID: HYP071
MIFTS: 48

Hypersensitivity Reaction Type Ii Disease

Categories: Immune diseases, Cancer diseases

Aliases & Classifications for Hypersensitivity Reaction Type Ii Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Ii Disease:

Name: Hypersensitivity Reaction Type Ii Disease 12 14
Autoimmune Diseases 52 41 69
Autoimmune Disease 12 29

Classifications:



External Ids:

Disease Ontology 12 DOID:417
ICD9CM 35 720
UMLS 69 C0003089

Summaries for Hypersensitivity Reaction Type Ii Disease

MedlinePlus : 41 your body's immune system protects you from disease and infection. but if you have an autoimmune disease, your immune system attacks healthy cells in your body by mistake. autoimmune diseases can affect many parts of the body. no one is sure what causes autoimmune diseases. they do tend to run in families. women - particularly african-american, hispanic-american, and native-american women - have a higher risk for some autoimmune diseases. there are more than 80 types of autoimmune diseases, and some have similar symptoms. this makes it hard for your health care provider to know if you really have one of these diseases, and if so, which one. getting a diagnosis can be frustrating and stressful. often, the first symptoms are fatigue, muscle aches and a low fever. the classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain and swelling. the diseases may also have flare-ups, when they get worse, and remissions, when symptoms get better or disappear. treatment depends on the disease, but in most cases one important goal is to reduce inflammation. sometimes doctors prescribe corticosteroids or other drugs that reduce your immune response.

MalaCards based summary : Hypersensitivity Reaction Type Ii Disease, also known as autoimmune diseases, is related to autoimmune disease of cardiovascular system and goodpasture syndrome, and has symptoms including autoimmune antibody positivity An important gene associated with Hypersensitivity Reaction Type Ii Disease is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Atenolol and Ramipril have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 An immune system disease that is an overactive immune response of the body against substances and tissues normally present in the body resulting from an abnormal functioning of the immune system that results in the production of antibodies or T cell directed against the host tissues.

Related Diseases for Hypersensitivity Reaction Type Ii Disease

Diseases in the Hypersensitivity Reaction Disease family:

Hypersensitivity Reaction Type Iii Disease Hypersensitivity Reaction Type Iv Disease
Hypersensitivity Reaction Type Ii Disease

Diseases related to Hypersensitivity Reaction Type Ii Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 344)
id Related Disease Score Top Affiliating Genes
1 autoimmune disease of cardiovascular system 33.1 CD40LG CD79A TLR9
2 goodpasture syndrome 32.0 APOH CD40LG CD79A CTLA4 IFNG IL10
3 pure autonomic failure 11.2 IL10 TNF
4 scirrhous adenocarcinoma 11.1 IL2 TNF
5 clopidogrel resistance 11.1 AIRE CTLA4 PTPN22
6 antigen-peptide-transporter 2 deficiency 11.1 CTLA4 PTPN22 TNF
7 alcoholic neuropathy 11.1 CD40LG CD79A
8 calloso-genital dysplasia 11.1 CD40LG CD79A
9 balkan hemorrhagic fever 11.1 CD40LG IL10
10 lung disease 11.1 CD40LG IL17A TNF
11 thyrotoxic exophthalmos 11.1 CD40LG TG
12 myoclonic astatic epilepsy 11.1 IFNG IL4
13 hereditary choroidal atrophy 11.1 IFNG IL17A TLR9
14 primary systemic mycosis 11.1 IFNG IL17A TNF
15 senile atrophy of choroid 11.1 CD79A TRIM21
16 intracortical osteogenic sarcoma 11.1 FOXP3 TG
17 atrichia with papular lesions 11.1 AIRE IFNG TNF
18 mu chain disease 11.1 CD40LG CD79A
19 rabies 11.1 CD40LG CD79A
20 familial retinoblastoma 11.1 CD40LG CD79A
21 anti-basement membrane glomerulonephritis 11.1 CD40LG CD79A
22 acute ackee fruit intoxication 11.1 IL10 IL4 TNF
23 autoimmune polyglandular syndrome type 3 11.1 IFNG IL2 TNF
24 microinvasive cervical squamous cell carcinoma 11.1 CD40LG CD79A
25 endocarditis 11.1 TNF TNFSF13B TRIM21
26 reproductive system disease 11.1 CD40LG IL10 IL17A
27 moderately severe hemophilia b 11.1 CTLA4 IL10 TNF
28 c1 inhibitor deficiency 11.1 APOH IL17A TNF
29 megaloblastic anemia 11.1 CD40LG IL10 TNF
30 brucella canis brucellosis 11.1 TLR9 TNF TRIM21
31 basidiobolomycosis 11.1 IL10 IL4 TNF
32 conjunctival deposit 11.1 CTLA4 TG TPO
33 lagophthalmos 11.1 IL10 IL4 TNF
34 amyotrophic lateral sclerosis type 10 11.1 IFNG IL2 TNF
35 fetal erythroblastosis 11.1 CD40LG CD79A
36 senile reticular retinal degeneration 11.1 IFNG IL10 TNF
37 graft-versus-host disease, protection against 11.1 IFNG IL10 IL2
38 spinal canal and spinal cord meningioma 11.1 CD40LG CD79A
39 uveitis 11.1 CD40LG CD79A TNF
40 trichostrongyloidiasis 11.1 CD40LG CD79A
41 parametritis 11.1 IFNG IL2 TNF
42 liver leiomyoma 11.1 IL10 IL4 TNF
43 glioblastoma multiforme 11.1 CD40LG IL10 TNF
44 indolent myeloma 11.1 CD40LG CD79A TNF
45 ileocolitis 11.1 CD40LG CD79A TNF
46 malignant eyelid melanoma 11.1 CD40LG CD79A IL17A
47 dysphagia 11.1 IFNG IL10 TNF
48 color blindness 11.1 AIRE TG TPO
49 adenohypophysitis 11.1 TG TPO
50 dermatomycosis 11.1 CD40LG CD79A TNF

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Ii Disease:



Diseases related to Hypersensitivity Reaction Type Ii Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Ii Disease

Human phenotypes related to Hypersensitivity Reaction Type Ii Disease:

32
id Description HPO Frequency HPO Source Accession
1 autoimmune antibody positivity 32 HP:0030057

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Ii Disease:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.47 IL2 IL4 MBP PADI4 PTPN22 TG
2 homeostasis/metabolism MP:0005376 10.43 AIRE APOH CD40LG CD79A CTLA4 FOXP3
3 immune system MP:0005387 10.41 AIRE CD40LG CD79A CTLA4 FOXP3 IFNG
4 cellular MP:0005384 10.34 AIRE CD40LG CD79A FOXP3 IFNG IL10
5 endocrine/exocrine gland MP:0005379 10.34 AIRE CD40LG CTLA4 FOXP3 IFNG IL10
6 mortality/aging MP:0010768 10.33 TRIM21 APOH CD40LG CTLA4 FOXP3 IFNG
7 growth/size/body region MP:0005378 10.32 AIRE FOXP3 IFNG IL10 IL17A IL2
8 digestive/alimentary MP:0005381 10.28 AIRE CTLA4 FOXP3 IFNG IL10 IL17A
9 liver/biliary system MP:0005370 10.13 IFNG IL10 IL2 IL4 PTPN22 TNF
10 craniofacial MP:0005382 10.02 FOXP3 IFNG IL10 IL17A IL4 TNF
11 no phenotypic analysis MP:0003012 10.02 AIRE CD79A FOXP3 IFNG IL10 IL17A
12 normal MP:0002873 9.97 AIRE CD79A CTLA4 FOXP3 IFNG IL10
13 renal/urinary system MP:0005367 9.91 IL4 PTPN22 TLR9 TRIM21 CD40LG CD79A
14 reproductive system MP:0005389 9.81 AIRE CD40LG FOXP3 IFNG IL10 IL2
15 respiratory system MP:0005388 9.65 IL2 IL4 PTPN22 TNF AIRE CTLA4
16 vision/eye MP:0005391 9.28 IFNG IL10 IL2 IL4 MBP TNF

Drugs & Therapeutics for Hypersensitivity Reaction Type Ii Disease

Drugs for Hypersensitivity Reaction Type Ii Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 574)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atenolol Approved Phase 4,Phase 2 29122-68-7 2249
2
Ramipril Approved Phase 4,Early Phase 1 87333-19-5 5362129
3
Ticlopidine Approved Phase 4 55142-85-3 5472
4
Amlodipine Approved Phase 4 88150-42-9 2162
5
Hydrochlorothiazide Approved, Vet_approved Phase 4,Early Phase 1 58-93-5 3639
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Linagliptin Approved Phase 4,Phase 2 668270-12-0 10096344
8
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
9
Voglibose Approved, Investigational Phase 4 83480-29-9 444020
10
Insulin Detemir Approved Phase 4 169148-63-4 5311023
11
Insulin-glulisine Approved Phase 4 207748-29-6
12
Ethanol Approved Phase 4 64-17-5 702
13
Liraglutide Approved Phase 4,Phase 3,Phase 1 204656-20-2 44147092
14
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
15
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
16
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
17
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3 56-81-5 753
18
Gliclazide Approved Phase 4,Phase 1,Phase 2 21187-98-4 3475
19
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
20
Insulin Lispro Approved Phase 4,Phase 3,Phase 1 133107-64-9
21
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
22
Methyltestosterone Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 58-18-4 6010
23
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 58-22-0 6013
24
Insulin Aspart Approved Phase 4 116094-23-6 16132418
25
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
26
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2 274901-16-5 6918537
27
Chromium Approved Phase 4,Phase 3 7440-47-3 27668
28
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
29
Glyburide Approved Phase 4,Phase 2 10238-21-8 3488
30
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
31
Saxagliptin Approved Phase 4,Phase 2 361442-04-8 11243969
32
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 122320-73-4 77999
33
Exenatide Approved, Investigational Phase 4,Phase 3 141758-74-9 15991534
34
Hydroxychloroquine Approved Phase 4 118-42-3 3652
35
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
36
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
37
Dapsone Approved, Investigational Phase 4 80-08-0 2955
38
Rifampin Approved Phase 4 13292-46-1 5458213 5381226
39
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
40
Telmisartan Approved, Investigational Phase 4,Phase 2 144701-48-4 65999
41
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
42
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
43
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
44
Ziprasidone Approved Phase 4 146939-27-7 60854
45
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
46
Menthol Approved Phase 4 2216-51-5 16666
47
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
48
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
49
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
50
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 925)

id Name Status NCT ID Phase Drugs
1 Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes Unknown status NCT01153243 Phase 4 Ergocalciferol;Placebo pill
2 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
3 Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes Unknown status NCT00925119 Phase 4 Atenolol
4 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
5 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
6 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
7 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
8 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
9 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
10 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
11 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
12 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity Unknown status NCT01736202 Phase 4
13 Multiple Grain in Type 2 Diabetes Unknown status NCT00337337 Phase 4
14 Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
15 Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding Unknown status NCT01597531 Phase 4 Liraglutide;Orlistat;Liraglutide + Orlistat
16 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
17 Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin. Unknown status NCT00404599 Phase 4 atrorvastatin 10mg;simvastatin 40mg
18 Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Unknown status NCT01253928 Phase 4 Pioglitazone
19 Fat, Inflammation and Insulin Resistance Unknown status NCT01054989 Phase 4
20 Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes Unknown status NCT02526810 Phase 4 insulin lispro;Insulin Glargine
21 Rationale and Design for Shiga Microalbuminuria Reduction Trial Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
22 Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects Completed NCT01589445 Phase 4 Pioglitazone hydrochloride;Metformin hydrochloride
23 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4 Valsartan
24 Effect of Thiazolidinedione Treatment Vascular Risk Markers Completed NCT00571506 Phase 4 Rosiglitazone;Pioglitazone
25 Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills Completed NCT00469105 Phase 4
26 The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers Completed NCT00339833 Phase 4 Salsalate;Placebo
27 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function Completed NCT00845182 Phase 4 Pioglitazone;Exenatide;Pioglitazone and Exenatide
28 Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
29 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
30 Activity and Metformin Intervention in Obese Adolescents Completed NCT00934570 Phase 4 Metformin and standard exercise;Metformin Intensive exercise
31 The Effect of Calcium Supplementation on Insulin Resistance and 24h Blood Pressure Completed NCT00549536 Phase 4
32 Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
33 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
34 Uniform Multidrug Therapy Regimen for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
35 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nep Completed NCT00168857 Phase 4 telmisartan;losartan
36 The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes Completed NCT01595789 Phase 4 Liraglutide;Placebo
37 Glucose and Lipid Metabolism on Antipsychotic Medication Completed NCT00515723 Phase 4 risperidone;olanzapine;quetiapine;ziprasidone
38 Molecular Mechanisms of Type 2 Diabetes Mellitus Completed NCT00816218 Phase 4 Pioglitazone
39 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
40 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
41 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) Completed NCT01560546 Phase 4 Testosterone;Placebo
42 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
43 Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes Completed NCT02049034 Phase 4
44 Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4? Completed NCT01040819 Phase 4 Pioglitazone
45 Can Vitamin D Supplementation Prevent Type 2 Diabetes? Completed NCT02112721 Phase 4
46 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
47 Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes Completed NCT01356381 Phase 4 Vildagliptin;Placebo
48 Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients Completed NCT00819325 Phase 4 pioglitazone;oral hypoglycemic agents
49 Quantiferon for Detection of Latent Tuberculosis in Healthcare Workers Completed NCT00797836 Phase 4
50 Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes Completed NCT00398853 Phase 4

Search NIH Clinical Center for Hypersensitivity Reaction Type Ii Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Hypersensitivity Reaction Type Ii Disease

Genetic tests related to Hypersensitivity Reaction Type Ii Disease:

id Genetic test Affiliating Genes
1 Autoimmune Disease 29

Anatomical Context for Hypersensitivity Reaction Type Ii Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Ii Disease:

39
Liver, Endothelial, T Cells, Heart, Kidney, Skeletal Muscle, Testes

Publications for Hypersensitivity Reaction Type Ii Disease

Variations for Hypersensitivity Reaction Type Ii Disease

Copy number variations for Hypersensitivity Reaction Type Ii Disease from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21625 1 159859611 159867782 Copy number FCGR3B Autoimmune disease
2 21792 1 161592989 161601158 Copy number FCGR3B Autoimmune disease
3 21796 1 161592989 161601158 Deletion FCGR3B Autoimmune disease
4 208909 6 211050653 211252076 Copy number CYP21B Autoimmune disease
5 210508 6 30400000 36600000 Copy number CYP21A Autoimmune disease
6 210509 6 30400000 36600000 Copy number TNXA Autoimmune disease
7 211044 6 3197570 32111174 Copy number C4A Autoimmune disease
8 211046 6 3197570 32111174 Copy number C4B Autoimmune disease

Expression for Hypersensitivity Reaction Type Ii Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Ii Disease.

Pathways for Hypersensitivity Reaction Type Ii Disease

Pathways related to Hypersensitivity Reaction Type Ii Disease according to GeneCards Suite gene sharing:

(show all 50)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CD40LG CD79A CTLA4 IFNG IL10 IL17A
2
Show member pathways
13.41 CD40LG IL10 IL17A IL2 IL4 TLR9
3
Show member pathways
13.39 CD40LG IFNG IL10 IL17A IL2 IL4
4
Show member pathways
13.31 CD40LG IL10 IL17A IL2 IL4 PTPN22
5
Show member pathways
12.87 IFNG IL10 IL2 TLR9 TNF
6
Show member pathways
12.8 IFNG IL2 IL4 TLR9 TNF
7
Show member pathways
12.71 CD40LG IL2 TLR9 TNF TNFSF13B
8
Show member pathways
12.71 CD40LG CD79A IFNG IL10 IL2 IL4
9
Show member pathways
12.67 CD40LG CTLA4 FOXP3 IFNG IL10 IL17A
10
Show member pathways
12.66 FOXP3 IFNG IL10 IL17A IL2 IL4
11
Show member pathways
12.59 IFNG IL10 IL17A IL2 TNF
12
Show member pathways
12.34 CD40LG CTLA4 IFNG IL10 IL17A IL2
13
Show member pathways
12.33 IFNG IL17A IL4 TNF
14
Show member pathways
12.3 CD40LG IFNG IL10 IL4 TNF
15 12.24 IFNG IL10 TLR9 TNF
16
Show member pathways
12.23 IFNG IL10 IL17A IL2 IL4 TNF
17
Show member pathways
12.22 IFNG IL10 IL2 IL4
18
Show member pathways
12.19 IFNG IL4 TLR9 TNF
19 12.09 IFNG IL2 IL4 MBP TNF TNFSF13B
20 12.06 CD79A IFNG IL10 IL2 IL4 TNF
21 12 IL10 IL17A IL4 TNF
22
Show member pathways
11.98 IFNG IL10 IL17A IL2 TLR9 TNF
23
Show member pathways
11.94 IFNG IL17A IL4 TLR9
24 11.94 CTLA4 IFNG IL17A TNF TNFSF13B
25 11.93 CD40LG CD79A CTLA4 FOXP3 IFNG IL10
26 11.84 IFNG IL10 IL2 TLR9 TNF
27
Show member pathways
11.81 CD40LG TNF TNFSF13B
28 11.79 IFNG IL2 IL4
29 11.78 IFNG IL10 IL17A IL2 IL4 TNF
30
Show member pathways
11.74 CD40LG TNF TNFSF13B
31
Show member pathways
11.72 CD40LG IFNG IL2 TNF
32